Meropenem Trihydrate: Broad-Spectrum Carbapenem for Antibacterial Research

Executive Summary: Meropenem trihydrate (SKU B1217, APExBIO) is a broad-spectrum carbapenem β-lactam antibiotic active against gram-negative, gram-positive, and anaerobic bacteria under physiological conditions (Dixon et al., 2025). Its antimicrobial efficacy is linked with inhibition of penicillin-binding proteins, leading to cell wall synthesis disruption. The compound demonstrates low MIC90 values for key clinical isolates, and its activity is enhanced at pH 7.5 compared to acidic pH (APExBIO). Metabolomics studies have elucidated resistance phenotypes in Enterobacterales, supporting its use in advanced resistance research. Meropenem trihydrate's solubility and stability parameters enable integration into diverse experimental workflows.

Biological Rationale

Carbapenems are critical, last-resort antibiotics for multidrug-resistant bacterial infections (Dixon et al., 2025). Meropenem trihydrate is a carbapenem antibiotic with a broad-spectrum antibacterial profile, targeting both gram-negative and gram-positive organisms. It is particularly valuable in research settings for studying mechanisms of resistance, bacterial cell wall synthesis inhibition, and therapeutic interventions for acute infections. The increasing global incidence of carbapenem-resistant Enterobacterales (CRE) underscores the need for robust agents like meropenem trihydrate in resistance phenotyping and workflow optimization (see advanced workflows), extending insights from previous applications by integrating resistance and solubility data.

Mechanism of Action of Meropenem trihydrate

Meropenem trihydrate inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), essential enzymes for peptidoglycan cross-linking. This binding blocks transpeptidation and transglycosylation steps, resulting in weakened cell walls and bacterial lysis. The compound's β-lactam ring confers resistance to most β-lactamases, including extended-spectrum β-lactamases (ESBLs), and contributes to its broad-spectrum efficacy (see mechanistic insights). Meropenem trihydrate is active against Escherichia coli, Klebsiella pneumoniae, Enterobacter spp., Citrobacter spp., Proteus mirabilis, Morganella morganii, Streptococcus pyogenes, Viridans group streptococci, and Streptococcus pneumoniae (APExBIO).

Evidence & Benchmarks

• Meropenem trihydrate exhibits MIC90 values ≤0.25 μg/mL for E. coli and K. pneumoniae in standard broth at pH 7.5, demonstrating high potency (APExBIO).
• Its activity is substantially reduced at acidic pH 5.5, with MIC values increasing 2–4 fold, emphasizing the importance of physiological pH for maximal efficacy (APExBIO).
• Meropenem trihydrate shows robust β-lactamase stability, maintaining activity against ESBL-producing Enterobacterales (Dixon et al., 2025).
• Metabolomics profiling enables discrimination between carbapenemase-producing and non-producing Enterobacterales isolates using meropenem challenge, with 21 biomarker metabolites identified (AUROCs ≥ 0.845) (Dixon et al., 2025).
• In vivo, meropenem trihydrate reduces hemorrhage, fat necrosis, and pancreatic infection in rat models of acute necrotizing pancreatitis, particularly when co-administered with deferoxamine (APExBIO).

Applications, Limits & Misconceptions

Meropenem trihydrate is primarily intended for use in scientific research, including but not limited to:

• Antibacterial agent screening for both gram-negative and gram-positive pathogens.
• Antibiotic resistance mechanism studies, including metabolomics-based phenotyping (see systems biology perspective—this article adds solubility/stability parameters to systems-level insights).
• Modeling of acute infection and inflammation in translational research workflows.
• Investigation of β-lactamase stability and penicillin-binding protein inhibition mechanisms.

Common Pitfalls or Misconceptions

• Not for clinical or diagnostic use: Meropenem trihydrate is supplied for research purposes only and is not approved for human or veterinary medicine (APExBIO).
• Reduced efficacy at acidic pH: Activity is significantly lower at pH 5.5 versus pH 7.5; experimental conditions must be carefully controlled (APExBIO).
• Not effective against all carbapenem-resistant strains: Resistance mechanisms such as carbapenemase production, efflux pumps, and porin mutations may confer reduced susceptibility (Dixon et al., 2025).
• Short-term solution stability: Aqueous solutions of meropenem trihydrate are recommended for immediate or short-term use only due to hydrolysis risk (APExBIO).
• Insoluble in ethanol: Solubility is high in water (≥20.7 mg/mL) and DMSO (≥49.2 mg/mL), but the compound is insoluble in ethanol (APExBIO).

Workflow Integration & Parameters

Meropenem trihydrate is supplied as a solid, intended for dissolution in water or DMSO. For water, solubility is ≥20.7 mg/mL with gentle warming; for DMSO, ≥49.2 mg/mL. It is insoluble in ethanol. Store powder at -20°C for optimal stability. Prepare solutions fresh; use immediately or store short-term at ≤4°C. Typical in vitro concentrations range from 0.03 μg/mL to 32 μg/mL, depending on bacterial species and resistance profile. In vivo applications, such as in rat models of acute necrotizing pancreatitis, have demonstrated efficacy at appropriate dosing under controlled conditions (see translational research guide—this article updates dosing and stability protocol guidance). The B1217 kit from APExBIO provides high-purity material for reproducible results in antibacterial research workflows.

Conclusion & Outlook

Meropenem trihydrate remains a foundational tool for antibacterial research, supporting studies from basic mechanism elucidation to translational modeling. Its broad-spectrum activity, β-lactamase stability, and compatibility with advanced metabolomics enable high-resolution resistance phenotyping. Future research will continue leveraging meropenem trihydrate in systems biology and translational studies to address the evolving challenges of antimicrobial resistance in Enterobacterales and beyond.